Bayer submits Eylea for new indication in Japan

FRANKFURT Thu Nov 28, 2013 2:11am EST

FRANKFURT Nov 28 (Reuters) - Bayer has submitted its Eylea eye medication, co-developed with Regeneron, for approval in Japan to treat Myopic Choroidal Neovascularization (myopic CNV), a cause of blindness.

In Japan, pathologic myopia and the associated myopic CNV is one of the most common causes of blindness, Bayer said.

Eylea, which also treats age-related macular degeneration (AMD) - the most common cause of blindness in the elderly - has been grabbing market share from rivals such as Roche AG's Lucentis since its launch in late 2011.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.